Presentations

Presentations
Home / Presentations

Presentations

DateTitleDownloads
02/16/17
"One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy” – Presentation by Dr. Derralynn Hughes
Download DocumentationPDF
02/16/17
“PRX-102 for treating Fabry disease – immunogenicity and PK results from a phase 1-2 study” – Presentation by Prof. David Warnock
Download DocumentationPDF
02/14/17
“Characterization of a chemically modified plant cell culture expressed human α-galactosidase-A enzyme for treatment of Fabry disease” – Presentation by Dr. Yoseph Shaaltiel
Download DocumentationPDF
01/09/17
Protalix BioTherapeutics Corporate Update January 2017
Download DocumentationPDF
12/02/16
Protalix BioTherapeutics Inc.Investor Presentation
Download DocumentationPDF
09/08/16
A Novel Treatment for Fabry Disease – IV Administration of Plant Derived alpha-gal-a Enzyme Safety and Efficacy, 1 Year Experience - Presentation by Raphael Schiffmann, M.D.
Download DocumentationPDF
06/07/16
Protalix BioTherapeutics Corporate Update June 2016
Download DocumentationPDF
03/03/16
PRX-102 α-Galactosidase-A; Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease
Download DocumentationPDF
06/17/15
AIR DNaseTM: Actin Inhibition Resistant Plant Cell Recombinant Chemically Modified Deoxyribonuclease I (DNase I) for the Treatment of Cystic Fibrosis; Presentation by Yoseph Shaaltiel, Ph.D.
Download DocumentationPDF
02/12/15
Novel Treatment for Fabry Disease; IV Administration of Plant Derived α-galactosiodase-A Enzyme, Phase 1/2 Safety and Efficacy Study; Interim Report;" Presentation by Ozlem Goker-Alpan, M.D.
Download DocumentationPDF
02/13/13
Long-Term Safety and Efficacy Data of Taliglucerase Alfa, a Plant Cell–Expressed Recombinant Glucocerebrosidase, in the Treatment of Naïve Gaucher Disease Patients: 36-Month Results
Download DocumentationPDF
02/13/13
A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease*
Download DocumentationPDF
02/13/13
Plant Cell–Expressed Recombinant Glucocerebrosidase: Taliglucerase Alfa as Therapy for Gaucher Disease in Adult Patients Previously Treated With Imiglucerase: 24-Month Results
Download DocumentationPDF